Search

Displaying results 181 - 190 of 679 in total
  1. Drug

    Fenobam

    go.drugbank.com/drugs/DB12931
    Investigational

    Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance

  2. Drug

    OT-730

    go.drugbank.com/drugs/DB16112
    Investigational

    OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).

  3. Drug

    Evalstotug

    go.drugbank.com/drugs/DB19410
    Investigational

    Evalstotug is under investigation in clinical trial NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck).

  4. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones.

  5. Drug

    Sus scrofa hair

    go.drugbank.com/drugs/DB10881
    Approved

    Wild boar hair is used in allergenic testing.

  6. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 Ma...

  7. Drug

    Cetuximab

    go.drugbank.com/drugs/DB00002
    ApprovedInvestigational

    [A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic

  8. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  9. Drug

    SPVN20

    go.drugbank.com/drugs/DB33936
    Experimental

    SPVN20 is under investigation in clinical trial NCT07807111 (Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy).

  10. Drug

    Povidone

    go.drugbank.com/drugs/DB11061
    ApprovedInvestigationalWithdrawn

    somewhat controversial, as it was demonstrated in a few clinical studies that the application of the compound in wounds was associated with impaired wound healing, reduced wound strength, or infection in open